Pierre Vandepapelière
GlaxoSmithKline Biologicals
89 rue de l'Institut
1330 Rixensart
Belgium
Name/email consistency: high
- Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vandepapelière, P., Horsmans, Y., Moris, P., Van Mechelen, M., Janssens, M., Koutsoukos, M., Van Belle, P., Clement, F., Hanon, E., Wettendorff, M., Garçon, N., Leroux-Roels, G. Vaccine (2008)
- Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vandepapelière, P., Lau, G.K., Leroux-Roels, G., Horsmans, Y., Gane, E., Tawandee, T., Merican, M.I., Win, K.M., Trepo, C., Cooksley, G., Wettendorff, M., Ferrari, C. Vaccine (2007)
- Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults. Vandepapelière, P., Rehermann, B., Koutsoukos, M., Moris, P., Garçon, N., Wettendorff, M., Leroux-Roels, G. Vaccine (2005)
- Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. Vandepapeliere, P., Barrasso, R., Meijer, C.J., Walboomers, J.M., Wettendorff, M., Stanberry, L.R., Lacey, C.J. J. Infect. Dis. (2005)
- Therapeutic vaccination against chronic viral infections. Vandepapelière, P. Lancet. Infect. Dis (2002)